Skip to Content
Diagnosed with ankylosing spondylitis? Biologics can help >>

Proben-C (colchicine / probenecid) Disease Interactions

There are 7 disease interactions with Proben-C (colchicine / probenecid):

Major

Colchicine (Includes Proben-C) ↔ Dic

Severe Potential Hazard, High plausibility

Applies to: Disseminated Intravascular Coagulation

Colchicine should be used with caution in patients with disseminated intravascular coagulation. Debilitated patients have an increased risk of developing colchicine toxicity.

References

  1. Vedia C, Mascort JJ, Carrasco I, Olive A "Colchicine and thrombopenia." Clin Exp Rheumatol 11 (1993): 458
  2. "Product Information. Colchicine (colchicine)." Lilly, Eli and Company, Indianapolis, IN.
Major

Colchicine (Includes Proben-C) ↔ Liver Disease

Severe Potential Hazard, High plausibility

Applies to: Liver Disease

The clearance of colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic hepatic impairment compared to healthy subject. No pharmacokinetic data are available for patients with severe hepatic impairment (Child-Pugh C). Caution is recommended when prescribing colchicine to these patients.

References

  1. Warnes TW, Smith A, Lee FI, Haboubi NY, Johnson PJ, Hunt L "A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report." J Hepatol 5 (1987): 1-7
  2. Kocak N, Yuce A, Gurakan F, Ozen H, Gogus S, Kale G, Caglar M "Colchicine in the treatment of hepatic fibrosis in children." Am J Gastroenterol 91 (1996): 179-80
  3. Stanley MW, Taurog JD, Snover DC "Fatal colchicine toxicity: report of a case." Clin Exp Rheumatol 2 (1984): 167-71
View all 7 references
Major

Probenecid (Includes Proben-C) ↔ Blood Dyscrasias

Severe Potential Hazard, Moderate plausibility

Applies to: Anemia, Bone Marrow Depression/Low Blood Counts

The manufacturer does not recommend the use of probenecid in patients with known blood dyscrasias. Aplastic anemia, leukopenia, hemolytic anemia and other anemia have been reported infrequently during administration of probenecid. Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency may increase the risk of probenecid-induced hemolytic anemia.

References

  1. Gutman AB "Uricosuric drugs with special reference to probenecid and sulfinpyrazone." Adv Pharmacol 4 (1966): 91-142
  2. "Product Information. Benemid (probenecid)." Merck & Co, Inc, West Point, PA.
  3. Sosler SD, Behzad O, Garratty G, et al "Immune hemolytic anemia associated with probenecid." Am J Clin Pathol 84 (1985): 391-4
View all 4 references
Major

Probenecid (Includes Proben-C) ↔ Dehydration

Severe Potential Hazard, High plausibility

Applies to: Dehydration, Diarrhea, Vomiting

Probenecid may promote lithiasis by increasing uric acid concentration in the renal tubules. Adequate hydration is necessary during therapy. Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of uric acid kidney stones and should be encouraged to consume additional amounts of liquid or given intravenous fluid. In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended. Maintenance of a slightly alkaline or neutral urine is also desirable.

References

  1. "Product Information. Benemid (probenecid)." Merck & Co, Inc, West Point, PA.
  2. Gutman AB "Uricosuric drugs with special reference to probenecid and sulfinpyrazone." Adv Pharmacol 4 (1966): 91-142
Major

Probenecid (Includes Proben-C) ↔ Uric Acid Nephrolithiasis

Severe Potential Hazard, High plausibility

Applies to: Uric Acid Nephrolithiasis, History - Nephrolithiasis, Gouty Nephropathy

The use of probenecid is not recommended in patients with a history of uric acid nephrolithiasis or a urinary urate excretion greater than 750 mg/24 hr. Probenecid may promote lithiasis by increasing uric acid concentration in the renal tubules. Adequate hydration is necessary during treatment. In general, a fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended. Maintenance of a slightly alkaline urine is also desirable.

References

  1. "Product Information. Benemid (probenecid)." Merck & Co, Inc, West Point, PA.
  2. Gutman AB "Uricosuric drugs with special reference to probenecid and sulfinpyrazone." Adv Pharmacol 4 (1966): 91-142
Moderate

Probenecid (Includes Proben-C) ↔ Pud

Moderate Potential Hazard, Low plausibility

Applies to: Peptic Ulcer, History - Peptic Ulcer

The manufacturer states that probenecid should be used with caution in patients with a history of peptic ulcer. Uricosuric agents can cause upper gastrointestinal irritation and aggravate or reactivate peptic ulcer. However, these effects have primarily been reported with another uricosuric agent, sulfinpyrazone. GI effects associated with probenecid are usually limited to nausea, vomiting, and anorexia.

References

  1. "Product Information. Benemid (probenecid)." Merck & Co, Inc, West Point, PA.
Moderate

Probenecid (Includes Proben-C) ↔ Renal Dysfunction

Moderate Potential Hazard, High plausibility

Applies to: Renal Dysfunction

Probenecid may not be effective in patients with chronic renal insufficiency, particularly if creatinine clearance is below 50 mL/min. Probenecid has been used in patients with some renal impairment but dosage requirements may be increased.

References

  1. Scott JT, O'Brien PK "Probenecid, nephrotic syndrome, and renal failure." Ann Rheum Dis 27 (1968): 249-52
  2. "Product Information. Benemid (probenecid)." Merck & Co, Inc, West Point, PA.

Proben-C (colchicine / probenecid) drug Interactions

There are 656 drug interactions with Proben-C (colchicine / probenecid)

Proben-C (colchicine / probenecid) alcohol/food Interactions

There is 1 alcohol/food interaction with Proben-C (colchicine / probenecid)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide